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ABSTRACT 
COMPARISON OF EPHEDRINE AND DOPAMINE TO MANAGE HYPOTENSION 
AND ASSESSMENT OF ARTERIAL WAVEFORM ANALYSIS TO MONITOR 
CARDIAC OUPUT IN DOGS UNDER ISOFLURANE ANESTHESIA 
Hui Cheng Chen 
University of Guelph, 2004 
Advisors: Dr. Melissa D. Sinclair 
Dr. Doris H. Dyson 
The first study cornpared the mrdiovascutar responses of ephedrine at 0.2 rngtkg, 
IV (repeated if inadequate response) and dopamine infusion at 5 pglkg/min, IV (doubled to 
-10 Irg/kg/min, IV, if inadequate response) to manage hypotension in chical canine cases 
during routine anesthetic management. Treatments were randomly assigned to treat 
hypotension (mean arterial pressure, MAP < 60 mm Hg) in 12 cases. When MAP 
- - 
--remained lower than 70 mm Hg at 10 minutes post treatment, the ephedrine bolus was 
repeated or the dopamine infusion was doubled. The pressure-elevating effect of 
ephedrine was found to last less than 5 minutes, with improvement in cardiac index (CI), 
-stroke volume index (SVI) and oxygen delivery index (D021), but a decrease in systemic 
vascular resistance (SVR) at 10 minutes. Repeating the ephedrine did not produce further 
improvement. The infusion of dopamine at 5 pglkglmin did not improve blood pressure 
(BP), CI, DO2[ or SVI within 10 minutes. Increasing the infusion to 10 pglkglmin improved 
BP within 5 minutes, and increased CI, DOzl and SVI by 10 minutes. The ephedrine 
boluses were less effective than the dopamine infusions to augment BP, but the 
improvement in CI,. D021 and SVI- by the end of the 20-minute study period was not 
different between treatments. 
The second study validated the use of a commercial system ( P U I S ~ C O ~ ~ )  that 
estimates cardiac output (CO) based on arterial pressure waveform analysis (PCO) in 
anesthetized dogs, and assessed the agreement between PC0 and lithium dilution CO 
(LID) during variable hemodynamic situations induced by changes in anesthetic depth 
and administration of inotropes (dopamine and dobutamine). Pressure waveform from 
the dorsal pedal artery was used to track the CO changes by the PC0 monitor following 
a one-point calibration with LiD. Analysis based on 48 pairs of CO measurements found 
that PC0 always produced higher readings than LiD during deep anesthesia but lower 
than LiD during dopamine infusions. Differences were not detected during light 
anesthesia or dobutamine infusions. The coefficient of correlation (r) was 0.6289. 
Tolerance limits varied according to treatment. Power to detect 30% or more difference 
between PC0 and LiD was 92.5%. It was concluded that PC0 can be used to monitor 
CO when conditions are similar to those during calibration with LID. Recalibration is 
recommended for accurate estimation of CO when hemodynamic conditions or pressure 
waveform change significantly. 
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The first study compared the cardiovascular responses of ephedrine at 0.2 mglkg, 
1V (repeated if inadequate response) and dopamine infusion at 5 pglkglmin, IV (doubled to 
10 pglkglmin, IV, if inadequate response) to manage hypotension in clinical canine cases 
during routine anesthetic management. Treatments were randomly assigned to treat 
hypotension (mean arterial pressure, MAP < 60 mm Hg) in 12 cases. When MAP 
remained lower than 70 mm Hg at 10 minutes post treatment, the ephedrine bolus was 
repeated or the dopamine infusion was doubled. The pressure-elevating effect of 
ephedrine was found to last less than 5 minutes, with improvement in cardiac index (CI), 
stroke volume index (SVI) and oxygen delivery index (D021), but a decrease in systemic 
vascular resistance (SVR) at 10 minutes. Repeating the ephedrine did not produce further 
improvement. The infusion of dopamine at 5 pglkglmin did not improve blood pressure 
(BP), CI, D021 or SVI within 10 minutes. Increasing the infusion to 10 pglkglmin improved 
BP within 5 minutes, and increased CI, D021 and SVI by 10 minutes. The ephedrine 
boluses were less effective than the dopamine infusions to augment BP, but the 
improvement in CI, D021 and SVI by the end of the 20-minute study period was not 
different between treatments. 
The second study validated the use of a commercial system ( P U I S ~ C O ~ ~ )  that 
estimates cardiac output (CO) based on arterial pressure waveform analysis (PCO) in 
anesthetized dogs, and assessed the agreement between PC0 and lithium dilution CO 
(LID) during variable hemodynamic situations induced by changes in anesthetic depth 
and administration of inotropes (dopamine and dobutamine). Pressure waveform from 
the dorsal pedal artery was used to track the CO changes by the PC0 monitor following 
a one-point calibration with LiD. Analysis based on 48 pairs of CO measurements found 
that PC0 always produced higher readings than LID during deep anesthesia but lower 
than LiD during dopamine infusions. Differences were not detected during light 
anesthesia or dobutamine infusions. The coefficient of correlation (r) was 0.6289. 
Tolerance limits varied according to treatment. Power to detect 30% or more difference 
between PC0 and LiD was 92.5%. It was concluded that PC0 can be used to monitor 
CO when conditions are similar to those during calibration with LiD. Recalibration is 
recommended for accurate estimation of CO when hemodynamic conditions or pressure 
waveform change significantly. 
CHAPTER l 
LITERATURE REVIEW 
HYPOTENSION 
1 .I .I Definition 
The word 'hypotension' means 'abnormally low blood pressure'. The arterial 
blood pressures are measured in terms of systolic, diastolic and mean levels. Normal 
systolic (SAP), mean (MAP) and diastolic (DAP) arterial blood pressure (BP) values for 
conscious, non-anesthetized small animals are approximately 100-1 60, 80-1 20 and 60- 
100 mm Hg respectively (Haskins, 1996). Hypotension during anesthesia has arbitrarily 
been defined as a MAP of less than 60 mm Hg, which generally corresponds to a SAP of 
less than 80 - 90 mm Hg (Wagner and Brodbelt, 1997; Gaynor et al., 1999; Smith, 
2002). Although not clearly defined as such, these values are probably based on the 
lower limit of the BP range in the normal population where vital organs, such as the brain 
and the kidney could maintain autoregulation of its blood supply. Below this lower limit, 
the organ blood flow may decline in proportion to the drop in the BP (Guyton and Hall, 
2000). Therefore, SAP below 80 mm Hg and MAP below 60 mm Hg are assumed to 
result in inadequate cerebral and coronary perfusion and may warrant therapy (Haskins, 
1996). The exact time required before negative consequences result is not clearly noted, 
but the extent of damage within these organs is assumed to be proportional to the time 
of hypotension. 
Despite the above general definition, MAP of 50-55 mm Hg has been set as 
the 'safe' lower limit for the practice of deliberate hypotension during anesthesia in 
human medicine (more detail in section 1.1.2) (van Aken and Miller, 2000), while a MAP 
of 70 mm Hg has been recommended as the lower limit to minimize post-anesthetic 
myopathy in large animals (Smith, 2002). Furthermore, the autoregulation curve may be 
shifted to the right in hypertensive patients such that a decrease in vital organ blood flow 
may occur at a MAP higher than 60 mm Hg and thus, hypotension should be defined at 
a MAP higher than 60 mm Hg in such patients. Therefore, the definition of hypotension 
based on 'acceptable' or 'safe' lower limit of BP may somewhat varies depending on 
disease states, the specific organ system of interest, organ reserve and related outcome 
measures. The rationale behind setting these lower limits should probably be based on 
adequacy of organ perfusion and oxygen delivery to meet tissue metabolic demand and 
maintenance of organ function. Hence, the 'safe' lower limit during anesthesia would 
also need to consider the alterations in hemodynamics and distribution of cardiac output 
induced by the various drugs, the patient's hydration and intra-vascular volume status 
and whether supplemented oxygen is used. 
1 .I .2 Relationship Between Pressure And Flow 
According to Ohm's Law, flow is directly proportional to the pressure difference 
between two points and inversely proportional to the resistance to the flow (Stoelting, 
1999; Cunningham, 2002). This relationship can be expressed mathematically as: 
Blood Flow (Q) = Pressure difference between two points (A P) 
Resistance to Flow (R) 
Applying this formula to the systemic blood flow, blood pressure and vascular resistance, 
the formula can be rewritten as: 
Cardiac output (CO) = Mean aortic pressure(MAP) - Right atrial pressure(RAP1 
Systemic vascular resistance (SVR) 
where; 
CO (Llmin) is the total amount of blood that flows through the systemic 
circuit in a defined period 
MAP and RAP (mmHg) are the respective pressures measured directly 
SVR (dynlseclcm~5) is a calculated parameter based on the above formula 
Since changes in the RAP are usually negligible compared to that of MAP, 
changes in MAP could be a reflection of changes in CO or SVR or both. Thus, a 
decrease in MAP does not necessarily mean a decrease in CO or vice versa; likewise 
MAP values may be normal despite a low CO when SVR is high. Since CO is a flow 
parameter, it is more relevant to systemic perfusion than BP (Haskins, 1996). 
Applying the formula (Q = A PIR) to a particular organ, blood flow to the organ is 
determined by the perfusion pressure (arterial pressure - venous pressure) and 
resistance of the blood vessels within that particular organ. Since all the organs of the 
systemic circulation are exposed to the same perfusion pressure (i.e. similar systemic 
arterial and venous pressure), differences in distribution of blood to the various organs 
are result of the differences in vascular resistance of each organ (Cunningham, 2002). 
The vascular resistance of an organ is determined mainly by the diameter of its 
high-resistance arterioles. Arteriolar vasoconstriction and vasodilation are the 
mechanism that decreases or increases the blood flow to the organ. It is also the 
mechanism underlying autoregulation of orgam blood flow to maintain a constant blood 
flow within certain limits. As systemic pressure drops and therefore perfusion pressure, 
,the arterioles vasodilate, up to a certain limit, where further drop in perfusion pressure 
results in parallel decline in organ blood flow. 
The cerebral perfusion pressure is expressed as the difference between MAP 
and intracranial pressure (ICP), and is more important to cerebral blood flow 
autoregulation than MAP (van Aken and Miller, 2000). In a normal man, normal cerebral 
oxygen metabolism can continue in spite of a reduction in cerebral blood flow 
corresponding to a cerebral perfusion pressure of 30 to 40 mm Hg. This pressure relates 
to a MAP of 30 to 40 mm Hg, measured at the level of the carotid artery when the skull is 
opened (i.e., ICP of 0). However, when MAP falls below 50 mm Hg, cerebral blood flow 
no longer responds to changes in arterial carbon dioxide tension. Therefore, a MAP of 
50 -55 mm Hg in normothermic patients represents the lowest MAP where 
autoregulation of the cerebral blood flow is still in force, and forms the basis for the 'safe' 
lower limit of deliberate hypotension during anesthesia, utilized to reduce intra-operative 
blood loss in healthy patients. It is also important to note that this 'safe' lower limit is 
based on normovolemic patients with supplemented oxygen. 
Coronary blood flow fluctuates depending on the state of cardiac contraction, 
and blood flow through the left heart is maximal during diastole. Therefore, coronary 
perfusion pressure is more dependent on the diastolic pressure and is defined as the 
difference between diastolic aortic pressure and left ventricular end-diastolic pressure 
(Kirk and Sonnenblick, 1982). Coronary blood flow is autoregulated over a perfusion 
pressure range of 0 to 140 mm Hg, independent of myocardial oxygen demand (Olsson, 
Bunger and Spaan, 1991) 
Autoregulation of renal blood flow and glomerular filtration rate are maintained 
when MAP is between 60 and 160 mm Hg (Guyton and Hall, 2000). However, when 
effective circulatory volume decreases, renal blood flow decreases regardless of 
perfusion pressure or presence of autoregulation (Lote, Harper and Savage, 1996). 
Therefore, underperfusion of kidneys is possible in face of hypovolemia, even though 
MAP is within the range for autoregulation of renal blood flow. On the other hand, no 
significant changes in pre- or post-op (up to 8 days) serum creatinine, blood urea 
nitrogen, serum or urinary electrolytes were observed following deliberate hypotension at 
50 mm Hg for an average of 100 minutes (Thompson et al., 1978). The sensitivity of 
such measurements to detect tissue damage is questionable, and the impact of such 
treatment may be detrimental on long-term renal function. The presence of adequate 
urine output (without use of diuretics) has been equated with sufficient renal perfusion, 
since glomerular filtration and urine production should cease when there is no renal 
perfusion (Aronson, 2000). In healthy, normovolemic human patients, significant 
reduction in urine output and endogenous creatinine clearance had been shown during 
periods of hypotension (average MAP of 49 mm Hg, for 55 minutes) (Behnia, Siqueira 
and Brunner, 1978; Behnia et al., 1982). However, these parameters returned to normal 
levels within one hour upon restoration of BP. 
The pressure-flow autoregulation is limited in the hepatic arterial bed and 
probably absent in the portal venous circulation (van Aken and Miller, 2000). Extrinsic 
control of hepatic blood flow occurs primarily through a1 -mediated vasoconstriction by 
the sympathetic nervous system innervation from T3 - T I  I (Stoelting, 1999). Change to 
the hepatic venous compliance plays an essential role in the overall regulation of CO 
and therefore, liver perfusion may be more dependent on CO and extrinsic control by the 
sympathetic nervous system. Profound changes in liver perfusion may occur during 
periods of hypotension (van Aken and Miller, 2000). 
Based on the above discussions, it is clear that systemic BP is not an exact 
indicator of organ blood flow or tissue perfusion. But it is the most practical and least 
invasive means of cardiovascular monitoring in the clinical setting (Wagner and Brodbelt. 
1997). Ideally, CO along with BP should be used to provide an assessment of global 
cardiovascular function. However, we are limited in our abilities to measure CO in clinical 
veterinary practice due to technical expertise required, cost of equipment and 
invasiveness of the methods. Used in conjunction with other clinical assessments such 
as mentation status, mucous membrane colour, capillary refill time, heart rate and urine 
output (when available), measurement of BP plays a valid indirect role in our clinical 
assessment of the cardiovascular function of veterinary patients. Analysis of venous 
oxygen saturation and partial pressure, and lactate level may also help with 
determination of adequate supply of whole body oxygen demands. Assessment of the 
actual end-organ perfusion could be as simple as measuring urine output (as an indirect 
indicator of renal perfusion) or as sophisticated as gastric tonometry (in assessment of 
the splanchnic circulation). 
1 .I .3 Causes Of Hypotension During Anesthesia 
In identifying the causes of hypotension it is useful to consider the determinants 
of BP and factors that could contribute to hypotension. Based on the relationship 
between CO, MAP and SVR explained above, and the negligible change in RAP, the 
formula can be simplified and rearranged as MAP = CO X SVR. Therefore, factors that 
cause a reduction in CO or SVR can reduce MAP and lead to hypotension. Cardiac 
output is the function of heart rate (HR) and stroke volume (SV) [CO = HR X SV], and 
SV can be reduced with reduced preload, increased afterload or reduced cardiac 
contractility (Muir and Mason, 1996). Thus, drugs or conditions that cause vasodilation 
will reduce SVR, and drugs or conditions that reduce HR or SV can contribute to 
decreased CO, and therefore, MAP. 
The pathophysiology of hypotension during anesthesia is multifactorial with the 
major contributing factors related to the cardiovascular effects of the anesthetic agents 
used and the clinical condition of the patient. While the extreme severity of disease 
condition in an animal may primarily be responsible, the effects of anesthetic agents on 
the cardiovascular system are usually partly responsible, hence anesthetic protocols are 
tailored to the pre-operative condition of the patient. Various injectable and inhalant 
anesthetic agents can directly affect HR, preload, afterload, myocardial contractility or 
SVR, resulting in decreased CO and/ or MAP (Mazzaferro and Wagner, 2001). 
Therefore, balanced anesthesia is preferred to minimize doses and the effects of any 
one particular agent on the cardiovascular system. However, even with these measures, 
hypotension under anesthesia can result. 
I .I .3.1 Effects Of Anesthetics And Adjuncts 
Various classes of anesthetic agents and adjuncts can be used to achieve the 
varying needs of analgesia, immobilization, unconciousness and muscle relaxation. In a 
survey of 66 small animal practices in Ontario in 1993, agents that were commonly used 
in the anesthetic management of a total of 8,087 canine cases included, acepromazine 
(68%), atropine (59%), butorphanol (37%), meperidine (28%), glycopyrrolate (lo%), 
thiobarbiturate (52%), ketamine-diazepam (26%), halothane (38%) and isoflurane (36%) 
(Dyson, 1998). All of these agents can affect the cardiovascular system. 
Acepromazine is a potent neuroleptic commonly used to calm and sedate an 
animal prior to anesthesia. Pre-anesthetic administration decreases the amount of 
general anesthetic required and may offer protection against cardiac dysrhythmias 
(Dyson and Pettifer, 1997). However, it is a potent a, antagonist that can cause 
peripheral vasodilation resulting in a dose-dependent decrease in BP (Popovic et al., 
1972; Muir and Hubbell, 1985). 
Atropine and glycopyrrolate are both anticholinergic agents that block the action 
of acetylcholine on the parasympathetic nervous system. Clinically, they are used to limit 
salivary secretions, to prevent bradycardia and associated bradyarrhythmias, or to 
deliberately increase HR (Muir et al. 2000). Their cardiovascular effects will be further 
discussed in section 1.1.4.1. 
Butorphanol (a kappa agonist) and meperidine (a mu agonist) are both opioids 
that are used mainly for their analgesic and sedative properties. Other mu agonists that 
are commercially available in North America include morphine, oxymorphone, 
hydromorphone, fentanyl, alfentanil and sufentanil. In general, opioids cause little 
cardiovascular depression (Stoelting, 1999) and rarely are causes of hypotension. The 
advantages of including an opioid in an anesthetic regimen are sedation, pre-, intra- and 
post-operative analgesia, reduction in the requirement of induction and maintenance 
anesthetics, and reversibility of their physiologic effects (Paddleford, 1999). However, 
depending on the opioid and dose used, they can cause respiratory depression, sinus 
bradycardia, excitement and emesis (Muir et al, 2000). Opioid-induced bradycardia in 
the presence of cardio-depressive or vasodilating agents, such as isoflurane (Tyner, 
Greene and Hartsfield, 1989), halothane (Torske, Dyson and Conlon, 1999), propofol 
(Smith et al., 1993), or acepromazine (Cornick and Hartsfield, 1992), may decrease CO 
and thus, MAP. Treatment of the opioid-induced bradycardia with an anticholinergic has 
been demonstrated to resolve the reduction in CO. Rapid intravenous injection of 
morphine and meperidine may cause hypotension via histamine release (Patschke, 
1977; Muldoon et al, 1987), thus, these opioids are usually administered intramuscularly. 
Thiopental is an ultrashort acting thiobarbiturate with a rapid onset and short 
duration of action. Depending on the level of sedation, an initial 112 - 213 bolus dose of 
thiopental may need to be administered to avoid the excitement stage. In humans, rapid 
administration of thiopental has been associated with a mild and transient fall in BP due 
to arteriolar dilation. In healthy patients, this decrease in BP could be masked by a 
compensatory sympathetic response of increased HR (Filner and Karliner, 1976). In 
healthy dogs, the administration of thiopental caused an initial increase in HR, a 
decrease in SV, with no change in CO. Blood pressures were elevated transiently while 
HR was elevated for up to 10 minutes (Turner and Ilkiw, 1990; Quandt et al., 1998). In 
the absence of compensatory increases in the sympathetic nervous system activity, the 
negative inotropic effect of thiopental can be demonstrated (Housmans et al., 1995). In 
hypovolemic dogs, MAP may be maintained or even elevated in some dogs while severe 
hypotension and death could occur in others (Burstein and Hershey 1943; llkiw et al., 
1991). The ability to compensate might depend on the degree of sympathetic activity at 
the time of thiopental administration, with more profound and disastrous effects 
developing in dogs that had a high degree of sympathetic activity present following 
hemorrhage (Ilkiw et al., 1991). 
Ketamine as an induction agent in normovolemic or hypovolemic dogs is 
associated with an increase in HR, BP and CO due to sympathetic stimulation (Haskins 
et al., 1985; Haskins et al., 1990; Mattson, 2003). In dogs, ketamine is often 
administered together with diazepam. Diazepam is a benzodiazepine with minimal 
effects on the cardiovascular system (Haskins et al., 1986; Stoelting, 1999). 
Cardiovascular stimulation is less apparent when ketamine is administered after 
diazepam (Haskins et al., 1986). However, when ketamine is administered at large 
doses (30 mglkg, IV) to dogs recovering from isoflurane anesthesia, transient decreases 
in BP, CO and SVR were noted (Muir and Hubbell, 1988). In vitro, ketamine had been 
demonstrated to have a direct negative inotropic effect (Rusy et al., 1990). Thus, 
although ketamine is usually used in critically ill patients, profound hypotension may still 
occur if the endogenous store of catecholamines is depleted or if the sympathetic 
nervous system is profoundly suppressed (Waxman et al., 1980). 
In addition to thiobarbiturates and ketamine, propofol is becoming an increasingly 
popular injectable anesthetic as it provides rapid and excitement-free induction and 
recovery in both premedicated and non-premedicated dogs. Duration of anesthesia 
results in little difference in the recovery characteristics due to the rapid metabolism that 
occurs even when tissue saturation impairs distribution (Watkins, Hall and Clarke, 1987). 
However, propofol is relatively expensive and has a limited shelf-life once the ampule is 
opened. It has been reported to produce dose-dependant cardiopulmonary depression, 
although in healthy dogs, propofol at 8 mglkg, IV did not affect cardiovascular 
parameters significantly (Quandt et al., 1998). In hypovolemic dogs, propofol at 6 mglkg, 
IV caused a rapid drop in MAP with no compensatory increase in HR (Ilkiw et al., 1992). 
Similarly, propofol at 2.5 mglkg, IV decreased MAP and CO with no effect on HR in dogs 
anesthetized under ketamine and fentanyl (Brussel et al., 1989). In another study 
performed in hypovolemic dogs, induction with propofol and diazepam, followed by 
tracheal intubation, resulted in an increase in HR while MAP was maintained (Mattson, 
2003). The mechanisms underlying the decrease in MAP with propofol include a 
decrease in preload, vascular resistance, as well as cardiac contractility (Claeys et al., 
1988; Goodchild and Serrao, 1989; Brussel et al., 1989). 
Inhalation anesthetic agents are often used to maintain general anesthesia. In 
North America, halothane, enflurane, isoflurane, desflurane and sevoflurane are 
available for use. Of these, halothane, isoflurane and sevoflurane may be the more 
commonly used agents in small animals, with isoflurane gaining popularity over the 
years (Dodman and Lamb, 1992; Dyson et al., 1998; Wagner and Hellyer, 2002). 
lsoflurane is likely the most commonly used inhalant in small animals. A survey by 
Wagner and Hellyer (2002) revealed 100% of their respondents used isoflurane while 
none used halothane or sevoflurane. Isoflurane's advantages over halothane include its 
low blood solubility, allowing more rapid induction and recovery (Steffey, 1996), and its 
relative lack of arrhythmogenicity (Hubbell et al., 1984; Pettifer et al., 1997). Both 
halothane and isoflurane caused dose-dependant decreases in MAP in healthy dogs 
(Page1 et al., 1991; Mutoh et al., 1997). The decrease in BP produced by halothane is 
mainly a consequence of decreases in myocardial contractility and CO, whereas with 
isoflurane, the drop in BP is attributable more to the decrease in SVR (Stoelting, 1999). 
As the end-tidal isoflurane (Et-iso) concentration was increased from the minimum 
alveolar concentration (MAC)' of 1.3% to 2 times MAC (2.6%) in dogs, MAP and SVR 
decreased, while CO was sustained by an increase in HR (Steffey and Howland, 1977). 
When used alone, isoflurane may only result in a MAP of less than 60 mm Hg starting at 
' MAC is the minimum alveolar concentration of the inhalant that produces immobility in 50% of 
subjects exposed to a supramaximal noxious stimulus 
2 times MAC (Steffey and Howland, 1977), but in combination with other anesthetics, 
hypotension may develop at a lower concentration. For example, a typical anesthetic 
protocol in a dog that consists of premedication with acepromazine (0.05 mglkg, IM) and 
butorphanol (0.2 mglkg) IM; induction with propofol (3-6 mglkg, IV); and maintenance 
with isoflurane at the typical end-tidal concentration of 1.2 - 1.4% may result in a MAP of 
- 60 mmHg (Vaisanen et al., 2002). Similarly, the administration of butorphanol at 0.2 
mglkg, IV in dogs under 1.7% Et-iso decreased MAP from 90 mm Hg to 61 mm Hg 
(Tyner, Greene and Hartsfield, 1989). Thus, with the potential additive cardio-depressant 
effects of various combinations of anesthetics with isoflurane, it is not surprising that 
hypotension is one of the most common complications that develop during anesthesia in 
small animals (Hosgood, 1998; Gaynor et al., 1999). 
1 .I .3.2 Clinical Conditions 
In a systemically ill patient, the underlying disease conditions may contribute to 
the development of hypotension during general anesthesia, making the correctly chosen 
anesthetic agents and dose even more critical. Examples of clinical conditions in 
systemically ill patients that can affect CO and SVR, the two determinants of BP, are 
presented using the background presented by the review by Day (2000) and Smith 
(2002). For further details on the shock syndrome and its relevance to veterinary 
medicine, please refer to the review by Day (2000). 
Bradycardia associated with hypothermia, electrolyte imbalance and underlying 
cardiac disease may become worse with the administration of anesthetics. Patients with 
cardiac disease may have reduced CO as a result of valvular disease, outflow tract 
obstruction (increased afterload), dilated cardiomyopathy (decreased contractility), 
pericardial disease (decreased preload) or unsynchronized cardiac rhythm 
